Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage
ayahuasca, show some potential to treat depression, anxiety, and addiction. Importantly …

This narrative state-of-the-art review paper describes the progress in the understanding and
treatment of Posttraumatic Stress Disorder (PTSD). Over the last four decades, the scientific …

The emerging therapeutic efficacy of ketamine and classical psychedelics for depression
has inspired tremendous interest in the underlying neurobiological mechanisms. We review …

Psychedelics represent one of the most promising classes of experimental medicines for the
treatment of neuropsychiatric disorders due to their ability to promote neural plasticity and …

Hallucinations limit widespread therapeutic use of psychedelics as rapidly acting
antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) …

A revamped interest in the study of hallucinogens has recently emerged, especially with
regard to their potential application in the treatment of psychiatric disorders. In the last …

Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike
any treatments currently available. Not only do they produce sustained therapeutic effects …

Ligands can induce G protein-coupled receptors (GPCRs) to adopt a myriad of
conformations, many of which play critical roles in determining the activation of specific …

Psychedelics, also known as classical hallucinogens, have been investigated for decades
due to their potential therapeutic effects in the treatment of neuropsychiatric and substance …

Psychedelics make up a group of psychoactive compounds that induce hallucinogenic
effects by activating the serotonin 2A receptor (5-HT2AR). Clinical trials have demonstrated …